ArticleHypertension research : official journal of the Japanese Society of Hypertension2019
Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- The relationship between kidney function and the soluble (pro)renin receptor in young adults: the African-PREDICT study.BMC nephrology · 2025Article
- (Pro)renin receptor antagonist PRO20 attenuates nephrectomy-induced nephropathy in rats via inhibition of intrarenal RAS and Wnt/β-catenin signaling.Physiological reports · 2021Article
- Circulating prorenin: its molecular forms and plasma concentrations.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
- Article
- Adrenal (Pro)renin Receptor Expression and Serum Soluble (Pro)renin Receptor Concentration in Primary Aldosteronism.International journal of endocrinology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism is characterized by inappropriate overproduction of aldosterone by adrenal lesions and leads to hypertension. Excess aldosterone causes organ damage; therefore, finding a biomarker for organ damage risk is vital. The (pro)renin receptor regulates the tissue renin-angiotensin-aldosterone system. The blood soluble (pro)renin receptor concentration is a candidate biomarker that reflects the activity of the tissue renin-angiotensin-aldosterone system. This study investigated the relationships between serum soluble (pro)renin receptor concentrations and indices of organ damage in patients with primary aldosteronism. We examined plasma aldosterone and serum soluble (pro)renin receptor concentrations in patients with primary aldosteronism and evaluated the relationships between these values and organ damage indices, such as the cardio-ankle vascular index, urinary albumin excretion, estimated glomerular filtration rate, and high-sensitivity C-reactive protein levels. We enrolled 121 patients with primary aldosteronism (46 males, 54.9 ± 12.2 years of age). Serum soluble (pro)renin receptor concentrations were significantly positively correlated with the cardio-ankle vascular index, urinary albumin excretion, and high-sensitivity C-reactive protein levels and negatively associated with estimated glomerular filtration rates, independent of other factors. Plasma aldosterone concentrations showed no significant relationships with these indices. In patients with primary aldosteronism, serum soluble (pro)renin receptor concentrations, but not plasma aldosterone concentrations, showed significant associations with organ damage, suggesting that the serum soluble (pro)renin receptor level could be a high-risk biomarker of organ damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.